Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
about
The use of psychotropic medication during pregnancy: how about the newborn?Antidepressant use in pregnancy: a critical review focused on risks and controversiesPrenatal antidepressant exposure: clinical and preclinical findings.Preschool outcomes following prenatal serotonin reuptake inhibitor exposure: differences in language and behavior, but not cognitive function.Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?Antidepressant use in pregnant and postpartum womenTreatment of nonpsychotic major depression during pregnancy: patient safety and challengesNeonatal adaptation in infants prenatally exposed to antidepressants--clinical monitoring using Neonatal Abstinence Score.Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance.Neurodevelopmental outcome for offspring of women treated for antenatal depression: a systematic reviewTaking antidepressants during late pregnancy. How should we advise women?Depression during pregnancyEarly neurological outcome of young infants exposed to selective serotonin reuptake inhibitors during pregnancy: results from the observational SMOK study.Myoclonic seizures in a preterm baby: is this a presentation of venlafaxine withdrawal?The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.Mother-infant antidepressant concentrations, maternal depression, and perinatal eventsNewborn neurobehavioral patterns are differentially related to prenatal maternal major depressive disorder and serotonin reuptake inhibitor treatmentSelective serotonin reuptake inhibitors in human pregnancy: to treat or not to treat?Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: Testing the hypotheses.Clomipramine concentration and withdrawal symptoms in 10 neonates.Affect Expression and Self-Regulation Capacities of Infants Exposed in utero to Psychotropics.Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feedingPerinatal Generalized Anxiety Disorder: Assessment and Treatment.Use of antidepressants during pregnancy in the Netherlands: observational study into postpartum interventions.Maternal depression and medication exposure during pregnancy: comparison of maternal retrospective recall to prospective documentationThe Roles of Maternal Depression, Serotonin Reuptake Inhibitor Treatment, and Concomitant Benzodiazepine Use on Infant Neurobehavioral Functioning Over the First Postnatal Month.A Multidisciplinary Approach to the Treatment of Co-occurring Opioid Use Disorder and Posttraumatic Stress Disorder in Pregnancy: A Case Report.The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta-analysis.Perinatal depression: treatment options and dilemmas.Discontinuation of antidepressants during attempts to conceive: a pilot trial of cognitive behavioral therapy for the prevention of recurrent depression.A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposureThe role of pharmacotherapy in the management of self-regulation difficulties in young childrenAntidepressant use during pregnancy: current controversies and treatment strategies.Teratogenic effects of coadministration of fluoxetine and olanzapine on rat fetusesDevelopmental changes in serotonin signaling: Implications for early brain function, behavior and adaptationSerotonin reuptake inhibitors in pregnancy: can genes help us in predicting neonatal adverse outcome?The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists
P2860
Q24625025-78D6030D-B19F-42F3-B611-3EB8CEBD9464Q28281407-FF887C66-D662-4A31-AD22-25D924E913A3Q30415540-CC249A7D-4BA9-470D-BAA0-121397C389B4Q33907544-4F2D9493-A7CF-4502-A6F7-A7782E21F257Q33940520-98FB732F-F586-4BE5-8C96-E65A48269D30Q34068023-25237A2F-BEB2-4775-90F2-A3B9F76A7209Q34237681-BD8046C8-4F78-46D8-8716-C48530D8397FQ34445231-0E11F469-B4AC-4658-A0FC-777767673435Q34467757-B0E06E78-4276-479E-8E8E-0BD561000FEAQ34544981-119721F9-1375-4492-845B-2B4E39EE2E77Q34682589-38E49AB5-C05E-4466-AC78-C8E12F3F0EACQ34682688-F1ACA972-D3F0-4A23-835D-E3B541DA7251Q34778571-64F4A011-B599-49FC-9C64-12D4C2C39D97Q34929021-53BBEAAF-AA52-45E6-A1BB-17DB6B7BAFABQ34981937-DD62CDF0-C2D7-4FA1-BEE3-141700446261Q35172179-86968A20-EC6C-4750-9C67-7AB8400F9C9DQ35549316-6970EB94-2753-4689-8D46-D4727276FCAEQ35608913-B6B30D6E-0EE7-4DBE-BDE5-9C18E01EE980Q35640478-BBF8F537-08CD-499A-B8F2-0B84F2322C3AQ35718651-36FFFAB0-6D23-4112-8027-6C61BDD937A7Q35786090-AC44BDBB-6D2C-45F0-9EEB-DF011636187BQ35827404-91FF9A22-2A43-4145-8499-AA24A72E69AFQ36108616-37A8E967-8974-447E-AD76-4C68AEF7C5A0Q36246581-123BBA25-6DC3-44EF-B929-FE6BB3084701Q36467145-13AA97D9-B3DA-4AF4-BA0E-8AE2FF355923Q36547279-3EA0DC42-4F2C-460D-A22A-41CFFDDE0365Q36603506-ECC96718-34A9-4B0F-A3CF-F30018770286Q36706789-3014C15B-E3DF-4F93-8196-0FD86802793FQ36737979-C476855C-2E08-4679-90E6-1A3E3BC19BE8Q37122812-219FB323-337E-4248-9232-CEF65CE0B747Q37202127-191F46F6-1624-414F-8925-CF3844407E85Q37204884-AF8EB101-5201-4F09-BB12-C769D40484CDQ37359227-CD0E77C9-AFA6-44B1-84B0-1913604C9ECAQ37556400-1F02966B-5934-4839-AACA-87BCAA52C355Q37643389-25E816A2-7D3C-450F-9513-54C93D8DE58AQ41912767-A9A9C2C7-4D6F-4F79-A290-6A18343B966DQ57696679-6A140C71-9A5F-460B-86D8-6E72285C614E
P2860
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Pharmacologic factors associat ...... chotropic medication exposure.
@en
Pharmacologic factors associat ...... chotropic medication exposure.
@nl
type
label
Pharmacologic factors associat ...... chotropic medication exposure.
@en
Pharmacologic factors associat ...... chotropic medication exposure.
@nl
prefLabel
Pharmacologic factors associat ...... chotropic medication exposure.
@en
Pharmacologic factors associat ...... chotropic medication exposure.
@nl
P2093
P356
P1476
Pharmacologic factors associat ...... ychotropic medication exposure
@en
P2093
Colleen E Fitzgerald
Shaila Misri
Tim F Oberlander
Wayne Riggs
Xanthoula Kostaras
P304
P356
10.4088/JCP.V65N0214
P577
2004-02-01T00:00:00Z